

## Scheme of Arrangement has been Implemented

**Brisbane**, **Australia**, **26 September 2022** – ResApp Health Limited (ASX:RAP) (**ResApp**) advises that the scheme of arrangement pursuant to which Pfizer Australia Holdings Pty Limited (a whollyowned subsidiary of Pfizer Inc, a global biopharmaceutical company) (**Pfizer**) will acquire all of the issued shares of ResApp (**Scheme**) has now been implemented.

All ResApp shares have been transferred to Pfizer. Eligible ResApp shareholders who held ResApp shares at the Scheme record date, being 7:00pm (AEST) Monday, 19 September 2022 (**Scheme Record Date**) were paid A\$0.208 in cash per each ResApp share held at the Scheme Record Date in accordance with the terms of the Scheme. Holders of options in ResApp also were paid the consideration payable for cancellation of their options in ResApp today.

###

## **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test; SleepCheckRx, a prescription-only smartphone application that screens adults for moderate to severe sleep apnoea; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. For more information, please visit www.resapphealth.com.au.

## **Contacts**

Dr Tony Keating CEO and Managing Director +61 430 180 659 tony@resapphealth.com.au Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
<a href="mailto:brian@resapphealth.com.au">brian@resapphealth.com.au</a>

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.